產(chǎn)品編號 | Abk003 |
英文名稱 | Rabbit Anti-EMT Research Antibody Assembly kit antibody |
中文名稱 | EMT標(biāo)志物抗體套裝 |
別 名 | EMT Research Antibody Assembly kit(E-Cadherin,N-Cadherin,Vimentin,Occludin,ZO-1) 上皮-間質(zhì)轉(zhuǎn)換(EMT)標(biāo)志物抗體套裝(E-Cadherin,N-Cadherin,Vimentin,Occludin,ZO-1); EMT標(biāo)志物抗體套裝 |
研究領(lǐng)域 | 腫瘤 細胞生物 細胞粘附分子 細胞表面分子 細胞外基質(zhì) |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應(yīng) | Human |
產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | kDa |
檢測分子量 | |
細胞定位 | 細胞漿 細胞膜 |
性 狀 | Liquid |
濃 度 | 1mg/ml |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
注意事項 | For research use only. Not intended for diagnostic or therapeutic use. |
PubMed | PubMed |
產(chǎn)品介紹 |
Epithelial-mesenchymal transition (EMT) is a biological process that allows epithelial cell to assume mesenchymal phenotype. EMT and its reverse process, mesenchymal-epithelial transition (MET), are originally defined in the context of developmental stages and re-engaged in adults during wound healing, tissue regeneration, organ fibrosis, and cancer progression. Epithelial cells normally interacts with basement membrane via its basal surface. During EMT, they lose their cell polarity and cell-cell adhesion, and gain mesenchymal cell phenotype, including enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, stem-like features, and increased production of ECM components. Accordingly, there is reprogrammed gene expression with EMT. Especially, some cytoskeleton proteins (such as cadherin family members), tight-junction proteins (such as Occludin and ZO-1) and intermediate filament of mesenchymal origin (such as Vimentin) undergo significant changes and serve as best EMT markers to evaluate EMT. EMT Research Antibody Assembly kit is one economical package of selected antibodies for most representative EMT markers, including E-Cadherin, N-Cadherin, Vimentin, Occludin, and ZO-1. These antibodies have been tested in a variety of applications and species. For specific application information of different antibodies, please refer to each individual antibody datasheet. EMT Research Antibody Assembly kit Rabbit Anti-E cadherin antibody (bs-1519R) Rabbit Anti-N-cadherin antibody (bs-1172R) Rabbit Anti-Vimentin antibody (bs-0756R) Rabbit Anti-Occludin antibody (bs-10011R) Rabbit Anti-ZO-1 antibody (bs-1329R) Database links: EMT Research Antibody Assembly kit Rabbit Anti-E cadherin antibody (bs-1519R) Rabbit Anti-N-cadherin antibody (bs-1172R) Rabbit Anti-Vimentin antibody (bs-0756R) Rabbit Anti-Occludin antibody (bs-10011R) Rabbit Anti-ZO-1 antibody (bs-1329R)
上皮-間質(zhì)轉(zhuǎn)換(EMT)是一個使上皮細胞呈現(xiàn)間質(zhì)細胞表型的生物學(xué)轉(zhuǎn)變過程,EMT及其反向過程,間質(zhì)-上皮轉(zhuǎn)換(MET),最初定義在早期發(fā)育階段,并在成年期重新參與到傷口愈合、組織再生、器官纖維化和癌癥進展等多種病理過程中。上皮細胞通常與基底膜緊密結(jié)合,在EMT過程中,它們失去細胞極性和細胞粘附并獲得間質(zhì)細胞表型,包括遷移能力、侵襲性、對凋亡的抗性增強、干細胞樣特征和ECM組分的增加。與此相應(yīng)很多基因表達也發(fā)生了重新編程,尤其是一些細胞骨架蛋白(如鈣粘素家族成員)、緊密連接蛋白(如Occludin和ZO-1)和間質(zhì)特有中間纖維(如Vimentin)發(fā)生了顯著變化。因此,這些蛋白可作為評價EMT的最佳標(biāo)志。 EMT標(biāo)志物抗體套裝極具性價比,包含了最具代表性的EMT標(biāo)記物,包括E-cadherin、N-cadherin、Vimentin、Occludin和ZO-1。這些抗體在多種應(yīng)用和物種中進行了測試。有關(guān)抗體具體使用信息,請參閱各個抗體產(chǎn)品數(shù)據(jù)表。 |
產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with ZO-1 monoclonal antibody, unconjugated (bsm-41327M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
25 ug total protein per lane of various lysates (see on figure) probed with Vimentin polyclonal antibody, unconjugated (bs-8533R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
25 ug total protein per lane of various lysates (see on figure) probed with N Cadherin monoclonal antibody, unconjugated (bsm-52389R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|